Blog

Home  /  Activities   /  EUnetHTA Joint Action 3 (2016 - 2020)   /  PTJA07 – “Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contraindications to such therapies” project plan is now available.

PTJA07 – “Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contraindications to such therapies” project plan is now available.

The final project plan of the assessment on ustekinumab is now available. The final assessment report will be published on 22nd October, 2019.

Please access the final project plan at this link:

PTJA07 – Final Project Plan